A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA ...

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic ...

A new blood-based diagnostic test (IsoPSA) for prostate cancer that evaluates structural changes in prostate-specific antigen could reduce unnecessary biopsies and identify the right patients that ...

A new blood test called IsoPSA has been developed by researchers, that helps in detecting prostate cancer and reduces the rate of biopsies by almost 50 percent. IsoPSA, a new blood test detects ...

A blood test now in the works could be a better predictor of prostate cancer than current PSA tests. It's called the IsoPSA. It's being developed by the Cleveland Clinic, the Cleveland VA Medical ...

IsoPSA Test Evaluates Prostate Cancer-Specific Structural Variants of the PSA Protein to Aid in the Diagnosis of High-Grade Prostate Cancer CLEVELAND, December 01, 2025--(BUSINESS WIRE)--Cleveland ...

Using the prostate-specific antigen test to screen for prostate cancer is controversial: First, doctors used to perform it on nearly every man over 50. Then in 2012, the U.S. Preventive Task Force ...

The US Food and Drug Administration (FDA) has granted approval for Cleveland Diagnostics’ IsoPSA in vitro diagnostic (IVD) kit, designed as an aid for physicians in deciding on prostate biopsy for men ...

CLEVELAND, Ohio (WPVI) -- A new blood test called the Iso-PSA is more accurate at predicting a man's risk at developing serious prostate cancer. In a study presented today, the Iso-PSA was better at ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its ...

CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...